Abstract
BackgroundCanakinumab, a human anti-IL-1β monoclonal antibody, has been licensed for the treatment of cryopyrin-associated periodic syndrome (CAPS), while few reports have shown benefit in patients with refractory familial Mediterranean fever...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have